Business

Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

Article content material

HONG KONG — Regencell Bioscience Holdings Restricted (NASDAQ:RGC) (“Regencell” or the “Firm”), an early-stage bioscience firm that focuses on analysis, improvement and commercialization of Conventional Chinese language Medication (“TCM”) for the remedy of neurocognitive issues and degeneration, particularly Consideration Deficit Hyperactivity Dysfunction (“ADHD”) and Autism Spectrum Dysfunction (“ASD”), at the moment introduced the pricing of its preliminary public providing (“Providing”) of two,300,000 extraordinary shares at a public providing value of $9.50 per extraordinary share. The extraordinary shares have been authorised for itemizing on the Nasdaq Capital Market and are anticipated to begin buying and selling on July 16, 2021 below the ticker image “RGC.”

Article content material

Regencell expects to obtain mixture gross proceeds of roughly $21.9 million from this Providing, earlier than deducting underwriting reductions and different associated bills. As well as, the Firm has granted the underwriters a 45-day choice to buy as much as a further 345,000 extraordinary shares on the public providing value, much less underwriting reductions. The Providing is predicted to shut on or about July 20, 2021, topic to the satisfaction of customary closing situations.

Proceeds from the Providing might be used to fund the second analysis examine, the Firm’s TCM formulae and merchandise, workers salaries, amenities rental, renovations and gear, product and mental property registrations, and dealing capital and different normal company functions.

The Providing is being performed on a agency dedication foundation. Maxim Group LLC is performing as sole book-running-manager for the Providing.

Hunter Taubman Fischer & Li LLC is performing as counsel to the Firm, and Loeb & Loeb LLP is performing as counsel to Maxim Group LLC in reference to the Providing.

A registration assertion on Kind F-1 referring to the Providing was filed with the Securities and Change Fee (“SEC”) (File Quantity: 333-254571) and was declared efficient by the SEC on July 15, 2021. The Providing is being made solely by way of a prospectus, forming part of the registration assertion. Copies of the ultimate prospectus referring to the Providing could also be obtained from Maxim Group LLC, 300 Park Ave, sixteenth Flooring, New York, NY 10022, at (212) 895-3745. As well as, a replica of the prospectus referring to the Providing could also be obtained by way of the SEC’s web site at www.sec.gov.

Earlier than you make investments, you need to learn the prospectus and different paperwork the Firm has filed or will file with the SEC for extra full details about the Firm and the Providing. This press launch doesn’t represent a proposal to promote, or the solicitation of a proposal to purchase any of the Firm’s securities, nor shall such securities be supplied or offered in the USA absent registration or an relevant exemption from registration, nor shall there be any supply, solicitation, or sale of any of the Firm’s securities in any state or jurisdiction through which such supply, solicitation, or sale can be illegal previous to registration or qualification below the securities legal guidelines of such state or jurisdiction.

About Regencell Bioscience Holdings Restricted

Article content material

Regencell Bioscience Holdings Restricted is an early-stage bioscience firm that focuses on analysis, improvement and commercialization of TCM for the remedy of neurocognitive issues and degeneration, particularly ADHD and ASD. The Firm began in Hong Kong in 2014 and accomplished its first analysis examine utilizing personalised TCM system in Hong Kong. The Firm goals to launch three liquid-based standardized TCM formulae candidates for gentle, average and extreme ADHD and ASD sufferers in Hong Kong first and subsequently to different markets as we deem applicable.

Ahead-Wanting Statements

All statements apart from statements of historic truth on this announcement are forward-looking statements, together with however not restricted to, the Firm’s proposed Providing. These forward-looking statements contain recognized and unknown dangers and uncertainties and are primarily based on present expectations and projections about future occasions and monetary traits that the Firm believes could have an effect on its monetary situation, outcomes of operations, enterprise technique, and monetary wants, together with the expectation that the Providing might be efficiently accomplished. Traders can determine these forward-looking statements by phrases or phrases reminiscent of “could,” “will,” “count on,” “anticipate,” “purpose,” “estimate,” “intend,” “plan,” “consider,” “potential,” “proceed,” “is/are prone to” or different related expressions. The Firm undertakes no obligation to replace forward-looking statements to replicate subsequent occurring occasions or circumstances, or modifications in its expectations, besides as could also be required by regulation. Though the Firm believes that the expectations expressed in these forward-looking statements are cheap, it can’t guarantee you that such expectations will develop into appropriate, and the Firm cautions buyers that precise outcomes could differ materially from the anticipated outcomes and encourages buyers to assessment different elements that will have an effect on its future leads to the Firm’s registration assertion and in its different filings with the SEC.

blank

View supply model on businesswire.com: https://www.businesswire.com/news/home/20210715006080/en/

logo

Contacts

Company:
James Chung
Chief Technique Officer
Regencell Bioscience Holdings Restricted
ir@rgcbio.com

For buyers in Asia Area:
Strategic Monetary Relations Restricted
Vicky Lee (852) 2864 4834
Brigid Lee (852) 2114 4313
Yvonne Lee (852) 2864 4847
SPRG_Regencell@sprg.com.hk

For buyers outdoors of Asia Area:
Lena Cati
The Fairness Group Inc.
Vice President
(212) 836-9611
lcati@equityny.com

#distro

https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/regencell-bioscience-holdings-limited-announces-pricing-of-approximately-21-9-million-initial-public-offering

Apkdownload

Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@interreviewed.com. The content will be deleted within 24 hours.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

9 − 8 =

Back to top button